China Biologic Products Holdings Inc said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.
Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.
The offer of $120 per share represents a premium of 16.3% to China Biologic’s Wednesday close of $103.10.
The buyer group includes Beachhead Holdings Ltd, CITIC Capital China Partners IV LP, PW Medtech Group Ltd, Parkfield International Ltd, HH Sum-XXII Holdings Ltd and V-Sciences Investments Pte Ltd.
In August 2018, China Biologic rejected a $3.9 billion offer from a consortium led by its former chief executive officer.
Source: Reuters.com